Finally, the multinational prospective randomized trials TAILORx [12] and clinical trial Rx for Positive Node, Endocrine Responsive Breast Cancer (RxPONDER) [13] recently demonstrated that adjuvant chemotherapy can be safely omitted in node negative and node positive (1-3 nodes) women with early-stage hormone receptor positive and HER2 negative (HR+/HER2-) breast cancer and Recurrence Score results 0 to 25. Here, NR4A1 is linked to breast carcinoma.